Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
With material news this can spike up several bucks in a flash
Someone putting in 9797 is code they need shares that have dried up. Holding ground buy and be happy. We get a update in mitral valve as a new fast track in USA and off to the races
Looks like 2 pm margin calls will go up After the price is paid
Hopefully getting enough of these studies done to show reducers efficacy and safety for second stab at the us. Valve is still undergoing studies and I don’t even think on humans yet with their new model. Once human studies start should bounce again
Trademark will get done maybe with change over won’t take long. If it did go though share price would have been plus 5$. Doubled up on shares was a good day to be a buyer. There are some big investors in this arena. I’m a small fry until you see my name as 5 percent own
Great opportunity with a non event company has not done enough yet to get approval we already knew that. The shelve was already in the works they thought might as well do it with shares on the floor. Hopefully the last of the bad days for this company. One of the big boys should head it up from here
Should have been 10$ today. Will have to what another 6 month maybe. Thanks for your shares.
Lowest I’ve seen in awhile could be f’ed but I doubt it sell all you got somebody will buy them grabbed 100 k
Computerized buying down here someone that wants to buy us will have someone buy all the float down here then offer for the rest I’m hoping Boston scientific or Edward life sciences will take 1/4 to1/2 a share swap. Let’s make a deal
Any day should be info on animal implants for valve data and starting human trials let’s get some information to the public.
CMS is giving to reducer a code in July. This will allow hospitals to bill Medicare for the procedure with strict guidelines. Does anyone know if they have met with Medicare on verbiage that will be printed.
Looks like the computers are in charge of trading this one will see reloaded today
Somebody to invest 76 million into a company worth 30 million show the potential. His share price with warrents about 1.60 price you can do a lot better than him purchasing at this price.
zeusgodmd... Sorry, gift, is the wrong word. However, what is the 30 day rule?
No less than 1$ over 90 then 90 days to improve we don’t have to worry about it with recent 76 million dollar gift from investment firm last month we have enough month to weather out the storms for 6 months
What is this rule with the NASDAQ, if a stock sells for less then $2 for 200 days, the stock is delisted? Am I wrong?
Actually the rocket will take off with the FDA approval. Their the last ones coming to the party.
Boston scientific bought another company for 1.3 billion today. I guess we wait until valve gets approval in Europe before company gets sold. I’ll take one or 2 share trade please
I’m ready for 2 for 1 share sell to Boston scientific
New investor put 76 million of his company’s money into this stock under 3 different entities at 2 dollars. He will rise this stock past 4 dollars sell half and be in for free. It’s the American way. This stock selling for peanuts. Good luck to all the big money here.
I am late for the party but just started my position 2000 shares @ $2
Moving up the stairs is a real positive here with NVCN. More people know to keep on watching them
* * $NVCN Video Chart 02-10-2021 * *
Link to Video - click here to watch the technical chart video
Shorts will cover. Uptrend is beginning along with volume.$$$$
I guess that depends on your entry point. What goes down must go back up! Patience and GLTU!
So did we all get screwed here, or what?
Seeing tons (like, literally dozens) of pro-NVCN posts across multiple boards that have been deleted since yesterday's pump.
I'd like to say "lesson learned," but by all appearances and DD this seemed to be a good buy... maybe a coordinated effort to P&D this stock?
Me and my expensive bags will be sitting here hoping to be proved wrong.
So did we all get screwed here, or what?
Seeing tons (like, literally dozens) of pro-NVCN posts across multiple boards that have been deleted since yesterday's pump.
I'd like to say "lesson learned," but by all appearances and DD this seemed to be a good buy... maybe a coordinated effort to P&D this stock?
Me and my expensive bags will be sitting here hoping to be proved wrong.
Valve patent approval in Europe to the moon
* * $NVCN Video Chart 02-09-2021 * *
Link to Video - click here to watch the technical chart video
Looking locked up. Shorts a 5 percent will have problems getting cheap shares more likely trying to buy back slowly but stock still moving up on them. At some point a panic upstick will happen
USA open your eyes to the data. This looks like it’s going to pop
Let the United States was money on admissions to the hospitals for chest pain only a couple billion a year. Money talks fda getting paid off
Supplemental info provides good summary and what’s next for valve slow ride but going upward
At least we have Germany and Europe
This stock has over 5 percent shorts. 1 million shares.
With cpt codes I’m hope Fred has some lobbyists to discuss language for use. Wording and indications for use language and criteria will be big when it comes out. There are panel meetings on it before the language is written. That’s why it will not be used til July 1st. There are dates for it and this stock will probably go up or down on it. I am thinking that we are focusing on the stock price of it too much. Valve deadlines and approvals are when this stock goes up big.
I guess nobody saw that we are getting a procedure code in USA in July first step in billing for Medicare. Similar code with tms procedures in psychiatry once approved and given guidelines printed with the code the procedure can be done if in the guidelines. If that is compassionate use for endstage angina I will take it for now. Then once they find out it works like the rest of Europe already using it will get a broader use
Fred needs to talk if there is going to be compassionate usage in the USA otherwise partner with Boston scientific and focus on the mitrial valve mission.
Never mind the USA is clueless and these guys probably getting paid off like the rest of the government
Anybody know timeline on fda granting compassionate use of reducer in USA. Meeting was end of November to discuss and granted it was safe but couldn’t read or understand it’s successful treatment for angina in Europe with all its articles in print.
Man this was a great buy. Thai is easily going towards $2
Followers
|
185
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
11968
|
Created
|
12/22/13
|
Type
|
Free
|
Moderators |
March 29th, 2018 3:07 AM EDT
Neovasc Inc. PT updated to $2.00 at Leerink Partners, states that 'Tiara Clinical Trials Continue to Progress' Maintains 'Outperform' Rating.
https://www.streetinsider.com/Analyst+PT+Change/Neovasc+%28NVCN%29+PT+Lowered+to+%242+at+Leerink+Partners%3B+Tiara+Clinical+Trials+Continue+to+Progress/13997143.html
March 29th, 2018
Canaccord Genuity Updates Neovasc Inc (US) (NVCN) Price Target to $0.50 and has a "Buy" rating.
https://registrarjournal.com/2018/03/29/canaccord-genuity-lowers-neovasc-inc-us-nvcn-price-target-to-0-50.html
Neovasc Inc. (Nasdaq: NVCN), a front-runner in minimally invasive transcatheter mitral valve technologies today announced that its board of directors (the "Board") has appointed Fred A. Colen as president and chief executive officer effective immediately. This leadership transition is a key element of the Company's strategy to support plans for the commercialization of its new-to-market Reducer™ ("Reducer") product in Europe and the advancement of its Tiara™ ("Tiara") mitral valve clinical program. Alexei Marko, Neovasc's outgoing CEO, will maintain his role as a Director on the Neovasc Board of Directors and continue to serve as an advisor to the Company.
"After ten years building Neovasc, I am convinced that now is the time for new leadership to take the Company to the next level. I am especially pleased that an industry leader of Fred Colen's caliber has accepted this opportunity," said Alexei Marko, outgoing CEO of Neovasc. "I look forward to my continued involvement as a board member."
Fred Colen has contributed to many significant turnarounds in his career, including the post-acquisition Guidant Company, which became the CRM division of Boston Scientific, a firm with which he held progressively senior executive roles over 11 years, including Chief Technology Officer from 2001-2008 and Member of the Executive Committee from 2001-2010. During his tenure at Boston Scientific, Mr. Colen is credited with numerous successes. As President of the company's Cardiac Rhythm Management (CRM) Group his team regained trust and confidence in the division's implantable pacemakers, leads, defibrillators and re-synchronization devices, increasing annual product revenue growth by over 10% in a flat US market and growing global divisional operating income from below 10% to 25% of sales, exceeding the planned annual free cash flow goals. As Chief Technology Officer, he led the development and global commercial launch for the Company's first- and second-generation implantable drug-eluting coronary stents (the Taxus Express and Taxus Liberte), leading to global market leadership with incremental revenues of US$2 billion annually. The Taxus Express market introduction is viewed as one of the most successful launches ever in the medical device industry.
Also note:
$BSX Boston Scientific laid off 300 employees just recently on March 27th, 2018 , perhaps to make room for the takeover of $NVCN ?? Who knows?? They already own 15% of NVCN.
source: https://www.massdevice.com/boston-scientific-lays-off-nearly-300-from-valencia-neuromod-facilities/
Our products include the Tiara™ technology in development for the transcatheter
treatment of mitral valve disease, the Neovasc Reducer™ for the treatment of
refractory angina.
A Canadian Biotech company, headquartered in Vancouver, B.C. Canada, we are a
publicly traded company, listed on NASDAQ: (NVCN) and the Toronto Stock
Exchange TSX: (NVC)
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |